Houston-based biotechnology firm DNAtrix said today that it has merged with VectorLogics, a firm developing products for the treatment of ovarian cancer. Financial details of the merger were not announced by the companies. DNAtrix is developing adenovirus-based oncolytic virus products for treating brain cancer. The firm's lead candidate is in clinical testing at the University of Texas M.D. Anderson Cancer Center.
Top NewsTuesday, October 23, 2012
DNAtrix Merges With VectorLogics